Neutralizing and binding antibodies to ifn-β: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations

Carolina Scagnolari, Giordano Dicuonzo, Guido Antonelli, Francesca Bellomi, Ombretta Turriziani, Francesca Bagnato, Valentina Tomassini, Vito Lavolpe, Marilena Ruggieri, Fabrizio Bruschi, Giuseppe Meucci

Research output: Contribution to journalArticle

Abstract

The frequencies of anti-interferon-β (IFN-β) antibody development reported to date in patients treated with different IFN-β preparations are not readily comparable mainly because of differences in underlying diseases and assay methods. Thus, the frequency of neutralizing antibody (NAb) and binding antibody (BAb) development was analyzed in a sample of sera derived from a homogeneous group of relapsing-remitting multiple sclerosis (RRMS) patients treated with different IFN-β preparations. The frequency of developing NAb and BAb to IFN-β varied according to the IFN-β given. Specifically, the NAb seroconversion frequency was significantly higher in patients treated with Betaferon, Schering AG, Berlin, Germany (31.3%) than in patients treated with both preparations of recombinant IFN-β1a (Rebif, Serono, Geneva, Switzerland [7.4%] or Avonex, Biogen, Cambridge, MA [6.3%]). Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-β preparations may also have different capability to induce BAb development and that BAb are produced during IFN-β therapy at a significantly higher rate than NAb. Our main conclusion is that different human IFN-β preparations may possess different immunogenicities, leading to varying frequency of development of antibody to IFN-β in RRMS.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalJournal of Interferon and Cytokine Research
Volume22
Issue number2
DOIs
Publication statusPublished - 2002

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Neutralizing Antibodies
Interferons
Antibodies
Berlin
Switzerland
Germany
Anti-Idiotypic Antibodies

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

Neutralizing and binding antibodies to ifn-β : Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. / Scagnolari, Carolina; Dicuonzo, Giordano; Antonelli, Guido; Bellomi, Francesca; Turriziani, Ombretta; Bagnato, Francesca; Tomassini, Valentina; Lavolpe, Vito; Ruggieri, Marilena; Bruschi, Fabrizio; Meucci, Giuseppe.

In: Journal of Interferon and Cytokine Research, Vol. 22, No. 2, 2002, p. 207-213.

Research output: Contribution to journalArticle

Scagnolari, C, Dicuonzo, G, Antonelli, G, Bellomi, F, Turriziani, O, Bagnato, F, Tomassini, V, Lavolpe, V, Ruggieri, M, Bruschi, F & Meucci, G 2002, 'Neutralizing and binding antibodies to ifn-β: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations', Journal of Interferon and Cytokine Research, vol. 22, no. 2, pp. 207-213. https://doi.org/10.1089/107999002753536176
Scagnolari, Carolina ; Dicuonzo, Giordano ; Antonelli, Guido ; Bellomi, Francesca ; Turriziani, Ombretta ; Bagnato, Francesca ; Tomassini, Valentina ; Lavolpe, Vito ; Ruggieri, Marilena ; Bruschi, Fabrizio ; Meucci, Giuseppe. / Neutralizing and binding antibodies to ifn-β : Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations. In: Journal of Interferon and Cytokine Research. 2002 ; Vol. 22, No. 2. pp. 207-213.
@article{354e54514f1e4b1fb3de6f794e95ffba,
title = "Neutralizing and binding antibodies to ifn-β: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations",
abstract = "The frequencies of anti-interferon-β (IFN-β) antibody development reported to date in patients treated with different IFN-β preparations are not readily comparable mainly because of differences in underlying diseases and assay methods. Thus, the frequency of neutralizing antibody (NAb) and binding antibody (BAb) development was analyzed in a sample of sera derived from a homogeneous group of relapsing-remitting multiple sclerosis (RRMS) patients treated with different IFN-β preparations. The frequency of developing NAb and BAb to IFN-β varied according to the IFN-β given. Specifically, the NAb seroconversion frequency was significantly higher in patients treated with Betaferon, Schering AG, Berlin, Germany (31.3{\%}) than in patients treated with both preparations of recombinant IFN-β1a (Rebif, Serono, Geneva, Switzerland [7.4{\%}] or Avonex, Biogen, Cambridge, MA [6.3{\%}]). Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-β preparations may also have different capability to induce BAb development and that BAb are produced during IFN-β therapy at a significantly higher rate than NAb. Our main conclusion is that different human IFN-β preparations may possess different immunogenicities, leading to varying frequency of development of antibody to IFN-β in RRMS.",
author = "Carolina Scagnolari and Giordano Dicuonzo and Guido Antonelli and Francesca Bellomi and Ombretta Turriziani and Francesca Bagnato and Valentina Tomassini and Vito Lavolpe and Marilena Ruggieri and Fabrizio Bruschi and Giuseppe Meucci",
year = "2002",
doi = "10.1089/107999002753536176",
language = "English",
volume = "22",
pages = "207--213",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Neutralizing and binding antibodies to ifn-β

T2 - Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-β preparations

AU - Scagnolari, Carolina

AU - Dicuonzo, Giordano

AU - Antonelli, Guido

AU - Bellomi, Francesca

AU - Turriziani, Ombretta

AU - Bagnato, Francesca

AU - Tomassini, Valentina

AU - Lavolpe, Vito

AU - Ruggieri, Marilena

AU - Bruschi, Fabrizio

AU - Meucci, Giuseppe

PY - 2002

Y1 - 2002

N2 - The frequencies of anti-interferon-β (IFN-β) antibody development reported to date in patients treated with different IFN-β preparations are not readily comparable mainly because of differences in underlying diseases and assay methods. Thus, the frequency of neutralizing antibody (NAb) and binding antibody (BAb) development was analyzed in a sample of sera derived from a homogeneous group of relapsing-remitting multiple sclerosis (RRMS) patients treated with different IFN-β preparations. The frequency of developing NAb and BAb to IFN-β varied according to the IFN-β given. Specifically, the NAb seroconversion frequency was significantly higher in patients treated with Betaferon, Schering AG, Berlin, Germany (31.3%) than in patients treated with both preparations of recombinant IFN-β1a (Rebif, Serono, Geneva, Switzerland [7.4%] or Avonex, Biogen, Cambridge, MA [6.3%]). Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-β preparations may also have different capability to induce BAb development and that BAb are produced during IFN-β therapy at a significantly higher rate than NAb. Our main conclusion is that different human IFN-β preparations may possess different immunogenicities, leading to varying frequency of development of antibody to IFN-β in RRMS.

AB - The frequencies of anti-interferon-β (IFN-β) antibody development reported to date in patients treated with different IFN-β preparations are not readily comparable mainly because of differences in underlying diseases and assay methods. Thus, the frequency of neutralizing antibody (NAb) and binding antibody (BAb) development was analyzed in a sample of sera derived from a homogeneous group of relapsing-remitting multiple sclerosis (RRMS) patients treated with different IFN-β preparations. The frequency of developing NAb and BAb to IFN-β varied according to the IFN-β given. Specifically, the NAb seroconversion frequency was significantly higher in patients treated with Betaferon, Schering AG, Berlin, Germany (31.3%) than in patients treated with both preparations of recombinant IFN-β1a (Rebif, Serono, Geneva, Switzerland [7.4%] or Avonex, Biogen, Cambridge, MA [6.3%]). Analysis of BAb seroconversion frequency in the same patients revealed that different IFN-β preparations may also have different capability to induce BAb development and that BAb are produced during IFN-β therapy at a significantly higher rate than NAb. Our main conclusion is that different human IFN-β preparations may possess different immunogenicities, leading to varying frequency of development of antibody to IFN-β in RRMS.

UR - http://www.scopus.com/inward/record.url?scp=18344374867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344374867&partnerID=8YFLogxK

U2 - 10.1089/107999002753536176

DO - 10.1089/107999002753536176

M3 - Article

C2 - 11911803

AN - SCOPUS:18344374867

VL - 22

SP - 207

EP - 213

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 2

ER -